Establishment Labs Holdings Inc. Logo

Establishment Labs Holdings Inc.

ESTA

(0.2)
Stock Price

43,96 USD

-27.05% ROA

-357.81% ROE

-12.74x PER

Market Cap.

903.290.500,00 USD

617.44% DER

0% Yield

-47.53% NPM

Establishment Labs Holdings Inc. Stock Analysis

Establishment Labs Holdings Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Establishment Labs Holdings Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

2 ROE

Negative ROE (-755.73%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-21.69%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (10.27x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The company has a high debt to equity ratio (339%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-83) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Establishment Labs Holdings Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Establishment Labs Holdings Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Establishment Labs Holdings Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Establishment Labs Holdings Inc. Revenue
Year Revenue Growth
2016 19.801.000
2017 34.681.000 42.91%
2018 61.208.000 43.34%
2019 89.565.000 31.66%
2020 84.676.000 -5.77%
2021 126.682.000 33.16%
2022 161.700.000 21.66%
2023 154.024.000 -4.98%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Establishment Labs Holdings Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 2.740.000
2017 6.864.000 60.08%
2018 12.687.000 45.9%
2019 14.991.000 15.37%
2020 13.793.000 -8.69%
2021 18.315.000 24.69%
2022 20.269.000 9.64%
2023 28.512.000 28.91%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Establishment Labs Holdings Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 0
2017 0 0%
2018 47.295.000 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Establishment Labs Holdings Inc. EBITDA
Year EBITDA Growth
2016 -15.531.000
2017 -20.005.000 22.36%
2018 -26.236.000 23.75%
2019 -32.142.000 18.37%
2020 -30.580.000 -5.11%
2021 -31.387.000 2.57%
2022 -42.748.000 26.58%
2023 -84.152.000 49.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Establishment Labs Holdings Inc. Gross Profit
Year Gross Profit Growth
2016 10.096.000
2017 17.702.000 42.97%
2018 36.118.000 50.99%
2019 54.861.000 34.16%
2020 52.502.000 -4.49%
2021 85.404.000 38.53%
2022 106.595.000 19.88%
2023 104.208.000 -2.29%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Establishment Labs Holdings Inc. Net Profit
Year Net Profit Growth
2016 -22.159.000
2017 -34.897.000 36.5%
2018 -21.098.000 -65.4%
2019 -38.150.000 44.7%
2020 -38.121.000 -0.08%
2021 -41.139.000 7.34%
2022 -75.209.000 45.3%
2023 -117.092.000 35.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Establishment Labs Holdings Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 -1
2017 -2 50%
2018 -1 -100%
2019 -2 0%
2020 -2 0%
2021 -2 0%
2022 -3 66.67%
2023 -4 25%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Establishment Labs Holdings Inc. Free Cashflow
Year Free Cashflow Growth
2016 -24.820.000
2017 -32.911.000 24.58%
2018 -35.657.000 7.7%
2019 -36.982.000 3.58%
2020 -16.417.000 -125.27%
2021 -34.261.000 52.08%
2022 -86.432.000 60.36%
2023 -37.867.000 -128.25%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Establishment Labs Holdings Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -14.266.000
2017 -31.970.000 55.38%
2018 -33.885.000 5.65%
2019 -29.983.000 -13.01%
2020 -12.510.000 -139.67%
2021 -27.532.000 54.56%
2022 -52.166.000 47.22%
2023 -31.511.000 -65.55%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Establishment Labs Holdings Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 10.554.000
2017 941.000 -1021.57%
2018 1.772.000 46.9%
2019 6.999.000 74.68%
2020 3.907.000 -79.14%
2021 6.729.000 41.94%
2022 34.266.000 80.36%
2023 6.356.000 -439.11%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Establishment Labs Holdings Inc. Equity
Year Equity Growth
2016 -26.435.000
2017 -5.013.000 -427.33%
2018 69.485.000 107.21%
2019 39.614.000 -75.41%
2020 74.961.000 47.15%
2021 50.739.000 -47.74%
2022 -8.185.000 719.9%
2023 30.487.000 126.85%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Establishment Labs Holdings Inc. Assets
Year Assets Growth
2016 29.562.000
2017 57.095.000 48.22%
2018 116.573.000 51.02%
2019 116.531.000 -0.04%
2020 156.388.000 25.49%
2021 139.529.000 -12.08%
2022 211.061.000 33.89%
2023 270.533.000 21.98%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Establishment Labs Holdings Inc. Liabilities
Year Liabilities Growth
2016 55.997.000
2017 62.108.000 9.84%
2018 47.088.000 -31.9%
2019 76.917.000 38.78%
2020 81.427.000 5.54%
2021 88.790.000 8.29%
2022 219.246.000 59.5%
2023 240.046.000 8.67%

Establishment Labs Holdings Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.81
Net Income per Share
-2.75
Price to Earning Ratio
-12.74x
Price To Sales Ratio
5.09x
POCF Ratio
-9.65
PFCF Ratio
-7.26
Price to Book Ratio
29.89
EV to Sales
5.86
EV Over EBITDA
-20.32
EV to Operating CashFlow
-11.01
EV to FreeCashFlow
-8.35
Earnings Yield
-0.08
FreeCashFlow Yield
-0.14
Market Cap
0,90 Bil.
Enterprise Value
1,04 Bil.
Graham Number
8.51
Graham NetNet
-4.34

Income Statement Metrics

Net Income per Share
-2.75
Income Quality
1.32
ROE
-4.68
Return On Assets
-0.29
Return On Capital Employed
-0.31
Net Income per EBT
1
EBT Per Ebit
1.21
Ebit per Revenue
-0.39
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.15
Stock Based Compensation to Revenue
0.08
Gross Profit Margin
0.65
Operating Profit Margin
-0.39
Pretax Profit Margin
-0.48
Net Profit Margin
-0.48

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.63
Free CashFlow per Share
-4.78
Capex to Operating CashFlow
0.32
Capex to Revenue
-0.17
Capex to Depreciation
-6.5
Return on Invested Capital
-0.26
Return on Tangible Assets
-0.27
Days Sales Outstanding
112.53
Days Payables Outstanding
168.01
Days of Inventory on Hand
394.55
Receivables Turnover
3.24
Payables Turnover
2.17
Inventory Turnover
0.93
Capex per Share
-1.16

Balance Sheet

Cash per Share
2,00
Book Value per Share
1,17
Tangible Book Value per Share
0.93
Shareholders Equity per Share
1.17
Interest Debt per Share
7.46
Debt to Equity
6.17
Debt to Assets
0.7
Net Debt to EBITDA
-2.66
Current Ratio
3.71
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
-0,05 Bil.
Invested Capital
6.17
Working Capital
0,14 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,05 Bil.
Average Payables
0,03 Bil.
Average Inventory
62152500
Debt to Market Cap
0.21

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Establishment Labs Holdings Inc. Dividends
Year Dividends Growth

Establishment Labs Holdings Inc. Profile

About Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

CEO
Mr. Juan Jose Chacon Quiros
Employee
908
Address
Building B15 and 25
Alajuela,

Establishment Labs Holdings Inc. Executives & BODs

Establishment Labs Holdings Inc. Executives & BODs
# Name Age
1 Mr. S. Ross Mansbach
General Counsel & Chief Compliance Officer
70
2 Ms. Rosalyn Cole d'Incelli
SVice President of Global Clinical, Medical & US Regulatory Affairs
70
3 Mr. Juan Jose Chacon Quiros
Founder, Chief Executive Officer & Executive Director
70
4 Mr. Ivan Bilic
Senior Vice President of Commercial Operations - OUS
70
5 Ms. Neeta Toprani
Corporate Secretary
70
6 Ms. Elizabeth Panzica Newman
Vice President & Head of U.S Business Unit
70
7 Mr. Rajbir Singh Denhoy
Chief Financial Officer
70
8 Mr. Roberto de Mezerville
Chief Technology Officer
70
9 Mr. Salvador Santos Dada
Head of Special Projects
70

Establishment Labs Holdings Inc. Competitors